Why Amgen Is Still King. Why Roche Allergic Asthma Drug Xolair Is Becoming a Blockbuster.

Repatha is the human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR). The binding  prevents PCSK9-mediated LDLR degradation, permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.

Repatha has been granted FDA approval as an adjunct to diet and maximally tolerated statin therapy . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.